Every 8-K that Lexicon Pharmaceuticals, Inc. (LXRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LXRX filings page.
Lexicon Pharmaceuticals reported second quarter 2026 results, with total revenues of $0.7 million, all from INPEFA net product sales, compared with $28.9 million a year earlier that included substantial licensing revenue from Novo Nordisk. Research and development expenses rose to $17.4 million and selling, general and administrative expenses to $9.8 million, resulting in a net loss of $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter.
Cash and investments were $190.6 million as of June 30, 2026, supported by $96.2 million of equity proceeds in February and a new $100 million loan facility with Hercules Capital, of which $55 million was drawn to refinance previous debt. Enrollment has been completed in the pivotal Phase 3 SONATA-HCM trial of sotagliflozin, with topline data expected in the first quarter of 2027, while an NDA resubmission for ZYNQUISTA in type 1 diabetes is anticipated in the fourth quarter of 2026. Novo Nordisk advanced LX9851 into Phase 1 for obesity, and Lexicon highlighted the potential for up to $1 billion in milestones and tiered royalties under that license.
Lexicon Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026, with total revenues of $21.1 million, up from $1.3 million a year earlier, driven mainly by $20.0 million of milestone revenue from its Novo Nordisk license.
Research and development expenses fell to $12.8 million and selling, general and administrative expenses declined to $9.2 million, reducing the quarterly net loss to $1.0 million from $25.3 million. Net product revenue from INPEFA was $1.1 million.
Cash, investments and restricted cash rose to $199.7 million as of March 31, 2026, helped by $96.5 million of equity proceeds in February. The company also put in place a $100 million loan facility with Hercules Capital, drawing $55 million to refinance prior debt.
Lexicon highlighted progress across its pipeline, including ongoing Phase 3 SONATA-HCM enrollment for sotagliflozin, anticipated mid-2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, Novo Nordisk’s Phase 1 program for obesity drug LX9851, and FDA clearance to advance pilavapadin into Phase 3 for diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals entered a new loan and security agreement with Hercules Capital providing up to $100 million in term loans maturing in May 2030. An initial $55 million tranche was funded at closing and will be used to repay Lexicon’s existing Oxford Finance loan facility.
The facility carries a floating interest rate equal to the prime rate plus 3.10%, with a floor of 9.85%, and an initial interest-only period of 18 months that can be extended up to 30 months upon achievement of specified clinical, regulatory and financial milestones. The loans are secured by a first lien on all assets and include minimum cash and revenue covenants and other customary restrictions.
In connection with the financing, Lexicon granted Hercules warrants to purchase up to 1,257,860 shares of common stock at $1.59 per share, exercisable for five years, issued in stages alongside the three loan tranches.
Lexicon Pharmaceuticals, Inc. converted its Series B Convertible Preferred Stock into common shares and expanded its equity plans and authorized share capital. On April 30, 2026, all 408,434.7 outstanding Series B preferred shares were automatically converted into 20,421,735 shares of common stock at a 50-to-1 ratio under the existing terms, relying on a Section 3(a)(9) exemption.
Stockholders approved a 2026 Equity Incentive Plan, increasing the common stock available for awards from 75,000,000 to 90,000,000 shares, and a 2026 Non-Employee Directors’ Equity Incentive Plan, increasing its pool from 4,000,000 to 6,000,000 shares. Both plans now run through February 12, 2036. Lexicon also filed a Seventh Amended and Restated Certificate of Incorporation, effective on filing, raising authorized common stock from 450,000,000 to 900,000,000 shares, with related charter and equity plan items and auditor ratification approved at the annual meeting.
Lexicon Pharmaceuticals reported 2025 results showing higher revenue and a sharply reduced loss while advancing its pipeline. Total revenues were $49.8 million in 2025 versus $31.1 million in 2024, largely driven by $45 million of licensing revenue from a Novo Nordisk agreement and $4.6 million of INPEFA net sales.
Net loss narrowed to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share, helped by major cost reductions. Research and development expenses fell to $61.1 million from $84.5 million, and selling, general and administrative expenses dropped to $37.3 million from $143.1 million, reflecting a strategic repositioning and reduced INPEFA marketing.
As of December 31, 2025, cash, investments and restricted cash totaled $125.2 million, and in February 2026 the company added approximately $96.7 million of net equity proceeds plus a $10 million milestone payment from Novo Nordisk. Key programs progressed, including SONATA-HCM Phase 3 enrollment surpassing 50%, planned 2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, and Phase 3 readiness for pilavapadin in diabetic neuropathic pain.
Lexicon Pharmaceuticals has arranged a large equity financing through a public stock sale and related private placements involving its longtime investor Invus. The company agreed to sell 32,000,000 common shares at $1.30 per share, with underwriters holding a 30‑day option for 4,800,000 additional shares, for expected gross proceeds of about $41.6 million (or $47.84 million if the option is fully exercised), before fees.
Concurrently, Invus affiliates are purchasing 22,400,000 common shares at the same price for a total of $29.12 million, and an Invus affiliate will buy multiple tranches of Series B convertible preferred stock at $65 per share for expected gross proceeds of about $23.86 million (or $30.03 million if an additional option is fully used). Each preferred share converts into 50 common shares once shareholders approve a new charter increasing authorized common stock, the board adopts and files that charter, and any required Hart‑Scott‑Rodino clearances are obtained. After the offerings and the preferred conversion, Invus and related entities are expected to hold about 51% of Lexicon’s outstanding common stock, giving them majority ownership.
Lexicon Pharmaceuticals updated investors on its cash position, fundraising plans and late-stage pipeline. The company ended 2025 with unaudited cash, investments and restricted cash of $125.2 million, which it believes is sufficient to support planned operations into 2027, subject to final audit.
Lexicon achieved a $10 million milestone payment in January under its Novo Nordisk licensing agreement and may earn up to an additional $20 million in milestones in 2026. The company launched an underwritten public offering of common stock and plans a concurrent private placement to an affiliate of Invus, L.P., its largest stockholder.
The SONATA pivotal Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy is targeting 500 patients, with enrollment completion anticipated in mid-2026 and topline results expected in the first quarter of 2027. The FDA raised no objections to advancing pilavapadin into Phase 3 for diabetic peripheral neuropathic pain, and pooled Phase 2 data showed a two-point average daily pain score reduction at 12 weeks with the 10 mg dose. FDA feedback also indicated that the investigator‑initiated STENO1 study of sotagliflozin may provide sufficient safety data to support a potential resubmission of the ZYNQUISTA NDA in type 1 diabetes in 2026.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement tied to its Open Market Sale Agreement with Jefferies, covering potential at‑the‑market sales of common stock with an aggregate sales price of up to $75,000,000 under its effective Form S‑3 shelf. The supplement relates to the shelf registration filed on August 2, 2024 and declared effective on August 15, 2024.
The company also corrected an inadvertent statement in the supplement that suggested Ernst & Young LLP audited the effectiveness of internal control over financial reporting as of December 31, 2024. As a smaller reporting company and non‑accelerated filer, Lexicon is exempt from that requirement, and EY did not perform such an audit. The notice does not constitute an offer or solicitation in jurisdictions where it would be unlawful.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement for an at-the-market (ATM) offering of up to $75,000,000 of common stock under its existing Form S-3, with Jefferies LLC as sales agent. The Shares may be offered and sold from time to time pursuant to the Open Market Sale Agreement.
As of November 6, 2025, no sales have been made pursuant to the Agreement. Vinson & Elkins L.L.P. provided a legal opinion on the validity of the Shares, filed as Exhibit 5.1.
Lexicon Pharmaceuticals, Inc. furnished a Form 8-K to disclose that it issued a press release reporting financial results for the quarter ended September 30, 2025.
The press release is provided as Exhibit 99.1 and the company states that the information in this report and the exhibit is being furnished under Item 2.02 for results of operations and financial condition, rather than filed for purposes of Exchange Act liability or incorporation by reference.
Lexicon Pharmaceuticals (LXRX) has resolved its Nasdaq listing deficiency. On 23 Jul 2025 the company received written notice from Nasdaq Listing Qualifications confirming that LXRX’s common stock has maintained a closing bid price at or above the $1.00 threshold long enough to regain full compliance with Rule 5550(a)(2). As a result, the prior non-compliance matter is formally closed and no further action is required by the company.
The 8-K contains no financial performance data, operational updates, or strategic announcements; its sole purpose is to inform investors that the risk of delisting has been removed. Regaining compliance preserves LXRX’s access to the Nasdaq Global Select Market, supporting share liquidity and investor confidence.
Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.
During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.
The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.